Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of ... For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments ... Lilly isn't stopping its ambitions in oncology care with just one treatment. Right now, the company ...

Edited excerpts from the interview: BT: Eli Lilly’s Mounjaro (tirzepatide) has garnered significant attention globally for its efficacy in managing obesity and type-2 diabetes. When can we ...

agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

leader of Eli Lilly and Company's diabetes business unit in Northern Europe, tells pharmaphorum how the company is working to support diabetes care in the UK amid the pandemic. As COVID-19 turned ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Eli Lilly is just weeks away from launching ... News of the impending GB launch has been welcomed by patient organisation Diabetes UK, whose head of care, Douglas Twenefour, said: “Supporting ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...